About Earli
Earli is a developer of cancer treatment devices designed to search for natural biomarkers. The company's mission is to make cancer a benign experience. Cancers are detected early when they are homogeneous and then located early, so they can be treated when the chances of survival are multiple times higher. Rather than rely on biomarkers that cancer may - or often may not - naturally provide, Earli's technology forces cancer cells to make a synthetic, non-human biomarker using a novel gene therapy approach called Synthetic Biopsy. The early cancer is then visible in a PET scanner. The same platform is also usable for therapeutics.
Open positions (3)
Company details
Funding
Total raised
$119.5M
Last stage
Series B
Investors
Founders
Sam Weissman
Co-founder of Earli who originated the core idea for the company's cancer detection technology.
Cyriac Roeding
Co-founder who was immediately fascinated by the idea and helped build the company.
LinkedInDavid Suhy
Gene therapy and techbio startup expert with two decades of experience taking a gene therapy product from inception to Phase 2 clinical trials.
LinkedInSanjiv (Sam) Gambhir
The late Dr. Sam Gambhir was a pioneering cancer imaging scientist and distinguished professor at Stanford University School of Medicine, known for his work on PET reporter gene technology.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.